Lexeo Therapeutics, Inc. (LXEO)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
Key ratios (FY2025)
-40.5%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $654.0K | — |
| Operating Income | -$109.26M | -$105.77M | -$68.51M | -$60.51M | — |
| Net Income | -$99.96M | -$98.33M | -$66.39M | -$59.28M | — |
| EPS (Diluted) | $-1.86 | $-3.09 | $-12.40 | $-36.36 | — |
| Total Assets | $268.69M | $146.94M | $139.81M | $97.08M | — |
| Total Liabilities | $22.02M | $30.10M | $26.27M | $25.00M | — |
| Shareholders' Equity | $246.67M | $116.84M | $113.53M | -$112.95M | -$55.60M |
| Cash & Equivalents | $63.00M | $35.01M | $121.47M | $77.33M | $135.86M |
| Operating Cash Flow | -$98.56M | -$81.15M | -$59.50M | -$54.56M | — |
| Capital Expenditures | $397.0K | $481.0K | $115.0K | $672.0K | — |
| Shares Outstanding | 73.00M | 33.07M | 26.65M | 1.61M | — |